Our Leaders
Servier’s ambition to improve patient care comes from the top. Our best-in-class executives pave the way for success.
About us
WHO WE ARE
At Servier Pharmaceuticals, we are dedicated to bringing the promise of tomorrow to the patients we serve.
We are a commercial stage, privately held United States pharmaceutical company. Launched by Servier Group, a unique global organization operating in more than 150 countries and governed by a non-profit foundation, Servier Pharmaceuticals has the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of biotech.
As a growing leader in oncology, Servier is committed to finding solutions that will address today’s challenges. The company’s oncology portfolio of innovative medicines is designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Currently, we have four medicines approved in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and cholangiocarcionoma (CCA). We have also accelerated our investment in hard-to-treat cancers, with more than 50% of research and development dedicated to oncology. Our goal is to serve our patients with the utmost treatment and care to improve the potential for survival.
Why We Serve
Everything we do is designed to improve the lives of the patients we serve. We are committed to supporting patients throughout their survivorship journey – from diagnosis, to remission and beyond.
This commitment is embodied by our Patient Engagement Team, which supports each project by focusing on how to address the challenges patients face throughout their treatment journey. The information and feedback that we receive from our patient network help us tailor our initiatives toward new partnerships that benefit and meet the needs of the patients.
As a privately held company, we have the freedom to do what many other publicly traded biopharmaceutical companies can’t: devote our energy toward putting patients and caregivers first. We can think about long-term opportunities and research that can move the needle for patients without being beholden to investor or shareholder pressure.
Facts & Figures
Leveraging our broad global presence, Servier Pharmaceuticals can take advantage of:
65
A heritage more than 65 years strong: first laboratory opened in France in 1954.
5
Research centers,
world-class R&D capabilities
16
Drug manufacturing sites
across the world
150
Presence in 150 countries
15
International centers of
therapeutic research
90
Commercial operations in over 90
countries worldwide
~
A robust, global pipeline
including projects at varying
stages of clinical development
Our identity is defined by the three V’s
Our focus on care and comfort is central to our values. We are daring to innovate to expand the possibilities and continue to grow.